Leif Bengtsson - Concepedia

Concepedia

Author

Leif Bengtsson

Vertex Pharmaceuticals (United States)

Also Known As

Bengtsson, L, L Bengtsson, L. Bengtsson, Leif Bengtsson

46

Publications

4.2K

Citations

15

H-Index

29

Concepts

All Affiliations

Vertex Pharmaceuticals (United States)Cornell University Goethe University Frankfurt The Royal Free Hospital University College London

LB

About

Leif Bengtsson is an author at Vertex Pharmaceuticals (United States) specializing in medicine, hepatology, and hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	423
2	Hepatology	6	6	141
3	Health Sciences	2	2	57
4	Gastroenterology	2	2	28
5	Clinical Immunology	1	1	116

Leif Bengtsson

×

20

Publications

4.2K

Citations

15

H-Index

	Year	Citations
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection Ira M. Jacobson, John G. McHutchison, Geoffrey Dusheiko, New England Journal of Medicine	2011	2.4K
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection Christophe Hézode, Nicole Forestier, Geoffrey Dusheiko, New England Journal of Medicine	2009	1K
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor Leona Bessonova, Nataliya Volkova, Mark Higgins, Thorax	2018	205
1369 TELAPREVIR SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL Ira M. Jacobson, Ian M. Catlett, Patrick Marcellin, Journal of Hepatology Clinical ImmunologyImmunodeficienciesImmunologyAntiviral TherapyAntiviral Response	2011	116
P70 Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV Treatment-Naïve patients: final results of phase 3 ADVANCE Study: Abstract P70 Table 1 Geoffrey Dusheiko, Leif Bengtsson, Nathalie Adda, Gut	2011	66
Telaprevir-Related Dermatitis Jean‐Claude Roujeau, Maja Mockenhaupt, Steven R. Tahan, JAMA Dermatology	2012	60
58 TREATMENT OF CHRONIC HEPATITIS C WITH TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON-ALFA-2A WITH OR WITHOUT RIBAVIRIN: FURTHER INTERIM ANALYSIS RESULTS OF THE PROVE2 STUDY G Dusheiko, Christophe Hézode, Stanislas Pol, Journal of Hepatology HepatologyHepatitis CThe Prove2 StudyViral HepatitisAntiviral Drug Development	2008	47
1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL J.‐P. Bronowicki, Christophe Hézode, Leif Bengtsson, Journal of Hepatology NeurovirologyImmunodeficienciesViral HepatitisImmunologyClinical Trials	2012	46
477 ANEMIA HAD NO EFFECT ON EFFICACY OUTCOMES IN TREATMENT-NAIVE PATIENTS WHO RECEIVED TELAPREVIR-BASED REGIMEN IN THE ADVANCE AND ILLUMINATE PHASE 3 STUDIES Mark Sulkowski, Ruhananhad P. Reddy, Nezam H. Afdhal, Journal of Hepatology Blood TransfusionHematologyClinical TrialsPharmacotherapyMedicine	2011	43
1162 RIBAVIRIN DOSE MODIFICATION IN TREATMENT-NAIVE AND PREVIOUSLY TREATED PATIENTS WHO RECEIVED TELAPREVIR COMBINATION TREATMENT: NO IMPACT ON SUSTAINED VIROLOGIC RESPONSE IN PHASE 3 STUDIES Mark S. Sulkowski, Stuart K. Roberts, Nezam H. Afdhal, Journal of Hepatology PharmacologyAntiviral Drug DevelopmentHepatitisVirologyAntiviral Therapy	2012	33

Page 1